Welcome to our dedicated page for MEDLINE SEC filings (Ticker: MDLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medline Inc. (MDLN) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures as it becomes and operates as a publicly traded company. Medline has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to an initial public offering of its common stock, and it has announced the effectiveness of that registration statement and the pricing and closing of an upsized initial public offering of Class A common stock on the Nasdaq Global Select Market.
As Medline continues to report as a public company, this page will surface filings such as registration statements, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, when available. These documents are where Medline provides detailed information about its med-surg products and supply chain solutions, its two operating segments (Medline Brand and Supply Chain Solutions), its revenue sources, risk factors and other material business information.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents in plain language. Instead of reading an entire registration statement or future 10-K, users can rely on AI-generated highlights that point to major business updates, capital structure changes, and disclosures related to Medline’s role as what it describes as the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products.
The filings page also connects users to real-time updates from the SEC’s EDGAR system as new Medline filings are posted. Over time, this includes information on executive and insider transactions reported on Form 4, as well as proxy statements that describe governance and compensation matters. Together, these tools allow users to follow MDLN’s regulatory history and understand how Medline presents its business and risks in official SEC documents.
Medline Inc. executive William J. Abrams reported a routine tax-related share disposition. On June 15, 2026, 1,308 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability from vesting restricted stock units. This was not an open-market sale, and Abrams continues to hold 16,546 shares directly after the transaction.
Medline Inc. Chief Human Resources Officer Christopher P. Shryock reported a routine tax-withholding transaction involving company stock. On the vesting of restricted stock units, 872 shares of Class A Common Stock were withheld at a value of $36.61 per share to satisfy his tax liability, as noted in the footnote. After this non-market disposition for taxes, he directly holds 11,031 shares of Medline common stock.
Medline Inc.'s Chief Operating Officer Stephen L. Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability. This was not an open-market sale. Following the withholding, Miller directly holds 23,899 shares, so he retains the vast majority of his equity position.
Medline Inc. Chief Legal Officer Alexander M. Liberman reported a routine tax-related share disposition. On the reported date, 872 shares of Class A Common Stock were withheld to cover his tax liability arising from the vesting of restricted stock units. After this withholding, he directly holds 11,031 shares of Medline Class A Common Stock. This event reflects a standard administrative step tied to equity compensation rather than an open-market sale.
Medline Inc. Chief Product Officer Amanda H. Laabs reported a routine tax-related share disposition. On the reported date, 1,889 shares of Class A Common Stock were withheld to cover her tax liability arising from the vesting of restricted stock units, at a value of $36.61 per share. After this withholding, she directly holds 23,899 shares of Medline common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.
Medline Inc. Chief Financial Officer Michael B. Drazin reported a tax-withholding disposition related to equity compensation. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover taxes, leaving him with 23,899 shares held directly.
Medline Inc. Chief Commercial Officer and 10% owner Douglas P. Golwas reported a mix of equity transactions involving Medline stock and partnership units. He exercised 100,000 Common Units of Medline Holdings, LP into 100,000 shares of Class A common stock, while an equivalent 100,000 shares of Class B common stock were automatically cancelled and returned to the issuer with no economic value exchanged.
Golwas then sold 38,034 Class A shares at a weighted average price of $37.05 per share and 61,966 Class A shares at a weighted average price of $36.60 per share, both under a pre-arranged Rule 10b5-1 trading plan. In a separate move tied to restricted stock unit vesting, 1,889 Class A shares were withheld to cover tax obligations. Following these transactions, he continues to hold significant direct Class A ownership and 365,864 Common Units of Medline Holdings, LP indirectly, each exchangeable one-for-one into Class A shares.
Medline Inc. director and Chief Executive Officer James M. Boyle reported a routine tax-related share disposition. The filing shows that 2,370 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability linked to vesting restricted stock units. After this non-market transaction, Boyle directly holds 29,369 shares of Medline Inc. common stock.
GALANTI RICHARD A reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. director Richard A. Galanti reported stock-based compensation awards rather than open‑market purchases. He received 5,387 shares of Class A Common Stock as a grant at a price of $0.00 per share, bringing his direct holdings to 16,392 shares. Footnotes explain these are restricted stock units that vest either on March 30, 2027 or on the earlier of the first anniversary of grant and the next annual meeting of stockholders.